• Home
  • Search Results

Search Results

Cancer - Multiple Myeloma
51 studies match your search

Immuno-Oncology Database

Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 19 more)
  • Immune System/Infections

The HealthScore Health Coaching Program

The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.

Age & Gender
  • 15 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Chronic Conditions
  • Mental and Emotional Health
  • and 4 more
Visit Location
100% Remote (online, phone, text)
Open

PERMIT - PERsonalized BioMarkers for Immunotherapy Treatment

Have you been diagnosed with multiple myeloma or high-risk smoldering multiple myeloma? If so, you may be able to take part in a research study looking at how drugs used to treat multiple myeloma work.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Open

Registry for Adults With Plasma Cell Disorders.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
By physician referral or invitation only

Diagnostic Delay

The purpose of this study is to identify specific barriers to preventing a late stage cancer diagnosis within communities identified in North Carolina as having a higher rate of advanced cancer diagnoses.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Bladder, Breast, Colorectal, and 11 more)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

The purpose of this study is to explore etentamig (ABBV-383) and its safety and tolerability as a monotherapy or combined with other anti-myeloma agents. This study aims to determine the safest dose of etentamig and if it produces meaningful anti-myeloma activity for participant with multiple myeloma (MM).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Visit Location
100% Remote (online, phone, text)

Parents' Communication with Children about Cancer: A Qualitative Study

To conduct focus groups and semi-structured interviews of parents with cancer - and their co-parents - about their experiences communicating with their minor children about cancer to inform the development of a communication intervention support tool.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Parents of Children
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Adaptation of a Patient Navigation Program Study

This study seeks to better understand the unmet needs and care preferences of young adult cancer patients and their caregivers. Interviews to gather this information will be used to tailor an existing, evidence-based patient navigation program to these needs and preferences.

Age & Gender
  • 18 years ~ 50 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Opinions and Perceptions
  • UNC or UNC Health employees
  • and 2 more
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Equity in Cancer Clinical Trial Opportunity and Participation (EQUITY)

This study seeks to understand how best to increase knowledge about clinical trials, best way of communicating information about clinical trials, and suggestions for improving clinical trial participation particularly among African Americans (AA).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast, Colorectal, Lung, and 2 more)
  • Healthy Volunteer or General Population
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

10-CBA: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. This protocol will allow access to cord blood units that are unlicensed.

Age & Gender
  • 1 months ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Chronic Conditions
  • Transplant
  • and 2 more
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research